reports
CELLTRION INCORPORATED sees a downgrade to Slightly Negative on accoun...
The independent financial analyst theScreener just lowered the general evaluation of CELLTRION INCORPORATED (KR), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date February 15, 2022, the closing price was K...
- Dave Nicoski
- Ross LaDuke
Vermilion Int'l Compass: Global Equity Strategy
Hong Kong, China Begin To Participate We remain bullish and believe the path of least resistance is higher for global equities in the coming weeks and months. Where it gets difficult is in predicting near-term expectations due to the current overbought conditions based on indicators such as RSI and the percentage of MSCI ACWI stocks above their 50-day MAs. At this stage it is tough to get too excited for additional and significant near-term appreciation because of short-term overbought conditio...
DLG DIALOG SEMICONDUCTOR PLC
BB BLACKBERRY LIMITED
600763 TOPCHOICE MEDICAL CORP. CLASS A
4733 OBIC BUSINESS CONSULTANTS CO. LTD.
300015 AIER EYE HOSPITAL GROUP CO. LTD. CLASS A
2207 MEITO SANGYO CO. LTD.
02308 EVOC INTELLIGENT TECHNOLOGY (H)
6758 SONY CORPORATION
4958 T. HASEGAWA CO. LTD.
01177 SINO BIOPHARMACEUTICAL LIMITED
A068270 CELLTRION INC.
2454 ALL ABOUT
3231 NOMURA REAL ESTATE HOLDINGS INC.
3092 ZOZO INC.
ASML ASML HOLDING N.V.
NIO NIO INC. SPONSORED ADR CLASS A
HAPV3 HAPVIDA PARTICIPACOES E INVESTIMENTOS SA
YY JOYY
1477 INC.
6732 ISHARES MSCI JAPAN MIN VOLATILITY (EX-REITS) ETF
SENSORTEK TECHNOLOGY
- Dave Nicoski
- Ross LaDuke
Vermilion Int'l Compass: Global Equity Strategy
Global Equities Stumbling Again We continue to believe global equities (ACWI-US) are likely to test the recent low made on March 23, with an undercut of roughly 10% also in the cards. This expectation is supported by price action during prior major waterfall declines in past recessionary periods. It is also worth noting that 15-25% rallies are to be expected within bear markets -- potentially multiple. During 2001-2002 the S&P 500 had two 20-25% rallies, and both ended up failing and breaking t...
4001 ABDULLAH AL OTHAIM MARKETS CO.
NXT NEXTDC LIMITED
DRREDDY DR. REDDY'S LABORATORIES LTD.
HIK HIKMA PHARMACEUTICALS PLC
600073 SHANGHAI MALING AQUARIUS (A) (SC SH)
000830 LUXI CHEMICAL GROUP CO. LTD. CLASS A
A0M368 BEIJING SHUNXIN AGRICULTURE CO. LTD. CLASS A
NESTLEIND NESTLE INDIA LTD.
9697 CAPCOM CO. LTD.
600429 BEIJING SANYUAN FOODS CO. LTD.
3349 COSMOS PHARMACEUTICAL CORPORATION
002511 C&S PAPER CO. LTD. CLASS A
002568 SHANGHAI BAIRUN INVESTMENT HOLDING GROUP CO. LTD. CLASS A
002697 CHENGDU HONGQI CHAIN (A)
01579 YIHAI INTERNATIONAL HOLDING LTD.
3293 AZUMA HOUSE
300529 JAFRON BIOMEDICAL CO. LTD. CLASS A
8194 LIFE
600486 JIANGSU YANGNONG CHEMICAL CO. LTD. CLASS A
7974 NINTENDO CO. LTD.
000061 SHENZHEN AGRICULTURAL PRODUCTS GROUP (A)
600872 JONJEE HI-TECH INDUSTRIAL AND COMMERCIAL HOLDING CO. LTD. CLASS A
7113 TOP GLOVE CORPORATION BHD.
A068270 CELLTRION INC.
3038 KOBE BUSSAN CO. LTD.
31V VINDA INTERNATIONAL HOLDINGS LIMITED
6AH AUSNUTRIA DAIRY CORP LTD
CNU CHORUS LIMITED
SSMS PT SAWIT SUMBERMAS SARANA TBK
603288 FOSHAN HAITIAN FLAVOURING & FOOD CO. LTD. CLASS A
SF STILLFRONT GROUP AB
MIPS MIPS AB
603233 DASHENLIN PHARMACEUTICAL GROUP CO. LTD. CLASS A
1579 NIKKEI225 BULL 2X ETF
603707 NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO. LTD. CLASS A
6669 WIWYNN CORP.
01765 HOPE EDUCATION GROUP (P CHIP)
BGA BIONEUTRA GLOB/D
300595 OVCTEK CHINA INC. CLASS A
03141 BMO ASIA USD INVESTMENT GRADE BOND ETF
002907 CHONGQING PHARSCIN PHARMACEUTICAL (A)
300783 THREE SQUIRRELS (A)
603605 PROYA COSMETICS (A)
300699 WEIHAI GUANGWEI COMPOSITES CO. LTD. CLASS A
Celltrion Healthcare reçoit un avis favorable du CHMP pour sa formula...
INCHEON, Corée du Sud--(BUSINESS WIRE)-- Celltrion Healthcare annonce ce jour que le Comité des médicaments à usage humain (CHMP) de l'Agence européenne des médicaments (EMA) a adopté un avis favorable pour le CT-P13 SC en vue d'une autorisation de mise sur le marché dans l'Union européenne (UE) pour les personnes atteintes d'arthrite rhumatoïde (AR). Le CT-P13 SC est la version sous-cutanée du Remsima® (infliximab biosimilaire, CT-P13). Cette recommandation sera évaluée par la Commission européenne, l'organe compétent pour l'approbation des médicaments dans l'UE. Une formulation sous-cutan...
Celltrion Healthcare Receives CHMP Positive Opinion for Novel Subcutan...
INCHEON, South Korea--(BUSINESS WIRE)-- Celltrion Healthcare today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for CT-P13 SC for marketing authorisation in the European Union (EU) in people with rheumatoid arthritis (RA). CT-P13 SC is the subcutaneous version of Remsima® (biosimilar infliximab, CT-P13). This recommendation will now be reviewed by the European Commission, which has the authority to approve medicines in the EU. A subcutaneous formulation has the potential to enhance treatment opt...
- Yang Ku Kang
Celltrion (068270.KS): Rapid growth still ongoing
- We maintain our BUY and our KRW360,000 target price on Celltrion in light of the likely US sales approval of Truxima and Herzuma in 2H18 and the long-term momentum to come from subcutaneous Remsima and Inflectra. - 1Q18 review: Results were in line with market expectations as the market share of Truxima, a rituxan biosimilar which made a European debut in 2017, expanded more rapidly compared with Remsima. Sales came in at KRW245bn (+25% YoY), operating profit at KRW116.5bn (...
CT-P13 (biosimilar infliximab) is comparable to reference infliximab a...
VIENNA--(BUSINESS WIRE)-- Twelve-month data from the Personalised Anti-TNF therapy in Crohn’s disease Study (PANTS) was presented at the 13th Congress of the European Crohn’s and Colitis Organisation (ECCO). The results indicate that the clinical effectiveness, safety and immunogenicity of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) in patients with Crohn’s disease (CD) is comparable to those treated with reference infliximab as well as those treated with adalimumab.1 The UK-wide, three-year prospective observationa...
Le CT-P13 (infliximab biosimilaire) est comparable à l’infliximab d...
VIENNE--(BUSINESS WIRE)-- Douze mois de données provenant de l’étude de thérapie anti-TNF personnalisée dans la maladie de Crohn (PANTS) ont été présentées lors du 13e congrès de l’Organisation Européenne de la Maladie de Crohn et de la Colite (ECCO). Les résultats indiquent que l’efficacité clinique, l’innocuité et l’immunogénicité du CT-P13 (infliximab biosimilaire) de Celltrion Healthcare sont similaires à celles d’un traitement avec l’infliximab de référence et l’adalimumab chez les patients atteints de la maladie de Crohn (MC).1 ...
Celltrion Receives Positive CHMP Opinion for Herzuma® for Trastuzumab...
INCHEON, South Korea--(BUSINESS WIRE)-- Celltrion, Inc. (KOSDAQ: 068270) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending that Herzuma® (trastuzumab biosimilar) be granted marketing authorization in the European Union (EU) for the treatment of patients with early breast cancer, metastatic breast cancer, or metastatic gastric cancer whose tumors have either HER2 overexpression or HER2 gene amplification. The CHMP’s opinion...
- Yang Ku Kang
- Yang Ku Kang
Pharmaceuticals/Biotech: Diagnosing the biologics and biosimilar marke...
Biologics to grow faster than traditional/chemical drugs Biologics are diversified into biological medicines (vaccines, blood components), genetically modified drugs (antibody drugs), cell therapy, gene therapy drugs, etc. These drugs require intensive R&D and costly production facilities, which naturally pose a high entry barrier. They have fewer side effects vs. chemical drugs and demonstrate great efficacy against certain diseases. They also grant a long patent protection per...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Le nouveau rapport de l’Organisation Européenne de la Maladie de Cr...
INCHEON, Corée du Sud--(BUSINESS WIRE)-- Celltrion Healthcare accueille avec joie la publication du récent énoncé de position de l’Organisation Européenne de la Maladie de Crohn et de la Colite (ECCO) sur l'utilisation des biosimilaires dans le cadre des maladies inflammatoires de l’intestin (MII). Un rapport qui encourage la transition du produit de référence infliximab vers l'infliximab biosimilaire.1 La déclaration d’ECCO couvre plusieurs aspects liés aux biosimilaires et présente ses positions clés :1 ...
New statement from European Crohn's and Colitis Organisation supports ...
INCHEON, South Korea--(BUSINESS WIRE)-- Celltrion Healthcare welcomes the publication of the latest position paper from the European Crohn’s and Colitis Organisation (ECCO) on the use of biosimilars for inflammatory bowel disease (IBD), which supports switching from reference infliximab to biosimilar infliximab.1 The ECCO statement covers several aspects related to biosimilars and the key positions are:1 Switching from the originator to a biosimilar in patients with IBD is acceptable following appropriate ...
Celltrion Healthcare présente des résultats positifs pour le CT-P10 ...
SAN DIEGO--(BUSINESS WIRE)-- De nouveaux résultats présentés à l’occasion du congrès annuel 2016 de l’American Society of Hematology (ASH) démontrent que le CT-P10 (candidat biosimilaire du rituximab) et le rituximab de référence sont équivalents en termes de pharmacocinétique (PC) chez les patients atteints d’un lymphome folliculaire à un stade avancé (LFA), une forme de lymphome non-hodgkinien (LNH). 1 Au total, 121 patients souffrant de LFA ont été recrutés selon un ratio de 1:1 (59 patients pour le CT-P10 et 62 patients p...
Celltrion Healthcare Presents Positive Results for CT-P10, Biosimilar ...
SAN DIEGO--(BUSINESS WIRE)-- New data presented at the 2016 American Society of Hematology (ASH) Annual Meeting demonstrate that CT-P10 (biosimilar rituximab candidate) and reference rituximab are equivalent in terms of pharmacokinetics (PK) in patients with advanced follicular lymphoma (AFL), a form of non-Hodgkin lymphoma. 1 A total of 121 AFL patients were enrolled in a 1:1 ratio (59 patients on CT-P10 and 62 patients on reference rituximab) to demonstrate PK similarity of CT-P10 to reference rituximab, each given in combi...
Celltrion Healthcare présente des données soutenant l’efficacité ...
WASHINGTON--(BUSINESS WIRE)-- Les nouvelles données présentées ce jour au congrès annuel de l’American College of Rheumatology (ACR) démontrent que le profil d’efficacité et d’innocuité du CT-P10 (rituximab biosimilaire) pour le traitement des patients atteints de polyarthrite rhumatoïde (PR) est comparable à celui des patients traités avec un rituximab princeps sur une période de 24 semaines.1,2 Un total de 372 patients atteints de PR (161 patients traités au CT-P10 et 211 patients au rituximab princeps) ont participé à un e...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.